Latest Novartis Kisqali® NATALEE analysis reinforces 25

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows...

Related Keywords

San Antonio , Texas , United States , Barcelona , Comunidad Autonoma De Cataluna , Spain , France , Switzerland , Paris , France General , Chicago , Illinois , Norway , Lugano , Ticino , American , Prnewswire Novartis , Jeff Legos , American Society Of Clinical Oncology , European Commission , Drug Administration , American Society Of Clinical Oncology Annual Meeting , European Medicines Agency , Pfizer Inc , Presentation At European Society For Medical Oncology , Facebook , Instagram , Vestre Viken Hospital , Novartis , Global Head Of Oncology Development At Novartis , Novartis Institutes For Biomedical Research , Novartis Pharmaceuticals Corporation , Exchange Commission , European Society Of Medical Oncology Congress , European Society For Medical Oncology , Linkedin , Akershus University Hospital , American Cancer Society , Astex Pharmaceuticals , University Of Texas Md Anderson Cancer Center , Antonio Breast Cancer Symposium , Breast Medical Oncology , Executive Vice President , Global Head , Oncology Development , Standardized Definitions , Efficacy End Points , American Society , Clinical Oncology , Annual Meeting , Clinical Benefit Scale , United States Food , Novartis Institutes , Biomedical Research , Prescribing Information , Safety Information , Clinical Oncology Annual Meeting , European Society , Medical Oncology , Virtual Plenary , Medical Oncology Breast Cancer , Advanced Breast , New England Journal , Medical Oncology Congress , San Antonio Breast Cancer Symposium , Accessed August , Practice Guidelines , Published March , Published April , Vestre Viken Hospital Trust , Neoadjuvant Treatment , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , Trade Show News , Clinical Trials Amp Medical Discoveries ,